Survodutide Research Peptide (RUO)

What is Survodutide?

Survodutide (development code BI 456906) is an investigational dual agonist of the glucagon receptor (GCGR) and the glucagon-like peptide-1 receptor (GLP-1R). It is a 29-amino-acid linear synthetic peptide conjugated to a C18 fatty di-acid moiety through a hydrophilic linker at a lysine residue, a structural design that promotes albumin binding and resistance to enzymatic degradation. Co-activation of the GLP-1 and glucagon receptors is studied for its combined effects on appetite, glycaemic control and energy expenditure.

As a peptide compound, survodutide (CAS 2805997-46-8, molecular formula C192H289N47O61, ~4231.69 g/mol) is characterised as a lyophilised powder. It is being studied in late-stage clinical trials for obesity and for metabolic dysfunction-associated steatohepatitis (MASH/NASH), and is currently investigational. It is not yet approved by the FDA, EMA or other major regulators, and no efficacy or therapeutic claims are made here.

How Survodutide Is Produced & Characterised

Survodutide is a synthetically demanding acylated peptide: the lipid side-chain conjugation at the lysine residue and the 29-mer length create opportunities for deletion sequences, diastereomers and incomplete acylation that must be tightly controlled. For peptides of this class, the established industry approach is optimised Fmoc solid-phase peptide synthesis (SPPS) with controlled side-chain conjugation, followed by purification on preparative dynamic axial compression (DAC) HPLC columns to resolve the target sequence sharply from closely related impurities.

Analytical characterisation typically combines UPLC/HPLC for purity with LC-MS impurity profiling to confirm the sequence and minor structural variants, and the purified material is lyophilised to a stable, uniform powder. This describes the general production and analytical methods associated with acylated peptides of this type.

Regulatory & Development Context

Survodutide is investigational and in clinical development. It is in Phase 3 trials for obesity and for metabolic dysfunction-associated steatohepatitis (MASH/NASH), and is not yet approved by the FDA, EMA or other major regulators. It has received US FDA Breakthrough Therapy designation and EMA PRIME access in MASH, designations that support and expedite ongoing development but do not constitute approval; its efficacy and safety have not been established for therapeutic use.

Within the broader peptide-API field, regulated development of investigational molecules typically involves documentation such as US-DMF dossiers and CTD Module 3 CMC sections, analytical validation packages to ICH Q2(R1), and stability data to support IND/IMPD-stage filings.

Research supply from Winhycare Pharma

Winhycare Pharma supplies research-grade Survodutide to research organisations and individual researchers for research and development purposes. Material is supplied at high purity (>99%) under stringent quality control with QC documentation, in secure packaging through global standard logistics, with dedicated technical assistance from our team. We focus on consistent quality and purity, reliable and timely supply, confidential and professional service, and long-term partnerships.

Research use only. Not for human or veterinary use, and not for use in food, drugs, medical devices or cosmetics.

To enquire, tell us the quantity you need, the purity grade, the documentation you require and the destination country. The buyer is responsible for complying with the import and use regulations that apply to Survodutide in their country.